Cycle Pharmaceuticals Launches Cycle Vita PKU™, an AI-Powered Smartphone App for On-The-Go Management of Phenylketonuria (PKU)
BOSTON--(BUSINESS WIRE)--Apr 22, 2025--
Cycle Pharmaceuticals (Cycle) has launched Cycle Vita PKU, an AI-powered app to help patients with PKU manage every aspect of their treatment plan.
PKU is an inherited disorder caused by a deficiency of the phenylalanine hydroxylase (PAH) enzyme needed to process phenylalanine (Phe), which is found in all foods containing protein. 1 Nearly all cases of PKU are diagnosed through newborn screenings, 2 and require lifelong adherence to a strict PKU diet. 3
It can be challenging for patients with PKU, or their caregivers, to keep on top of everything, like medication, medical formula, lab results and diet. The app is designed to offer flexible and timely support with daily tracking, reminders and diet management tools. Users can plan their meals with a searchable food database of over 9,000 foods, as well as an AI-powered meal scanner that estimates Phe levels with a photo snap of the meal.
For adolescents and young adults, who are gaining independence and navigating the transition to adulthood, Cycle Vita PKU may be a helpful aid for adhering to their medication and a Phe-restricted diet on-the-go.
'The launch of Cycle Vita PKU marks an exciting milestone as the first app from Cycle Vita™, Cycle's dedicated patient support platform. As part of Cycle's commitment to the PKU community, Cycle will continue to innovate and find new ways to provide support tailored to patients' needs. Cycle Vita PKU is just one example of that commitment.' says Jamie Ray, Director - Patient Support Program, Cycle.
Cycle Vita PKU does not provide medical advice, diagnosis or treatment. Always seek the advice of your healthcare provider with any questions you may have.
References
Cycle Vita™ and Cycle Vita PKU™ are trademarks of Cycle Pharmaceuticals Ltd.
©2025 Cycle Pharmaceuticals Limited. All rights reserved.
US-VITA-2500003. February 2025
About Cycle Pharmaceuticals
Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease patient community. Cycle focuses on rare metabolic, immunological, and neurological genetic conditions. Within neurological conditions, we focus on multiple sclerosis. Cycle is headquartered in Cambridge, UK and has offices in Boston, Massachusetts. For more information, please visit www.cyclepharma.com and follow us on X, LinkedIn and Facebook.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250410778512/en/
CONTACT: [email protected]
Cycle Pharmaceuticals
Tel: +44 1223 354 118
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY FDA OTHER HEALTH HEALTH GENERAL HEALTH PHARMACEUTICAL NEUROLOGY RESEARCH GENETICS SCIENCE CLINICAL TRIALS
SOURCE: Cycle Pharmaceuticals
Copyright Business Wire 2025.
PUB: 04/22/2025 09:48 AM/DISC: 04/22/2025 09:48 AM
http://www.businesswire.com/news/home/20250410778512/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Emulate Launches AVA™ Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform
BOSTON--(BUSINESS WIRE)--Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented magnitude of in vivo -level insights faster than animal models while cutting consumable costs four-fold and in-lab labor by half compared to current generation technologies. These transformative capabilities give the pharmaceutical industry the practical means to pivot beyond animal testing and into truly human-relevant territory. With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program. Share 'AVA gives scientists unprecedented experimental capacity with the biological depth of live human tissue—something no other platform can match,' said Jim Corbett, Chief Executive Officer at Emulate. 'By combining Emulate's proven Organ-on-a-Chip technology with high-throughput consumables, automated imaging, and streamlined workflows in one benchtop unit, AVA lets teams ask bigger questions earlier and move the right drug candidates forward faster.' AVA Emulation System: Three Instruments in One AVA is the first self-contained Organ-on-a-Chip workstation to fuse high-throughput microfluidic tissue culture, full environmental control, and real-time imaging into a single, compact benchtop unit. Key performance gains include: Expanded experimental power – 96 independent Organ-Chip samples in a single run enable researchers to achieve microplate-level scale of their Organ-Chip experiments, enabling side-by-side comparison of dozens of compounds, doses, or stimuli. Lower operating costs – AVA achieves a four-fold drop in consumable spend and up to 50% fewer cells and media per sample compared to previous generation technology. Time & labor savings – Hands-on, in-lab time is reduced by more than half, thanks to automated microscopy, remote monitoring, and the revolutionary new Chip-Array™ consumable that integrates 12 independent Organ-Chips into an SBS format for streamlined workflows with multichannel pipettes and automated liquid handlers. AI-ready datasets – A typical 7-day experiment can generate >30,000 time-stamped data points from daily imaging and effluent assays, with post-takedown omics pushing the total into the millions—providing a rich, multi-modal foundation to feed machine-learning pipelines for target discovery, lead optimization, and safety prediction. A Timely Answer to Shifting Regulations With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program—has already outperformed animals, showing 87% sensitivity and 100% specificity for drug-induced liver injury in a 2022 Communications Medicine study. AVA now scales that level of human relevance across discovery, efficacy, and toxicology screens, accelerating safer therapies through the pipeline. 'Moving towards reduction and in some cases replacement of animal models demands both biological fidelity and throughput,' noted Dr. Lorna Ewart, Emulate Chief Scientific Officer. 'AVA meets those dual requirements, empowering teams to rank-order lead candidates, pinpoint off-target toxicities, and advance safer therapies with unprecedented speed and confidence.' Broad Impact Across Industries In biopharma, this type of reduction and replacement is already a reality. A leading pharmaceutical company has demonstrated the power of implementing Organ-Chips into their development pipeline when one of their scientists saved millions of dollars and years of development time by using Emulate Liver-Chips ahead of non-human primates to screen lipid-nanoparticle (LNP) candidates. AVA's leap in throughput of predictive human biology stands to benefit not only biopharma but a wide spectrum of sectors that currently rely on inaccurate animal testing. Large pharmaceutical pipelines can now run comparable screens in a single AVA experiment, while smaller biotech teams gain enterprise-level capacity without adding headcount or infrastructure. Beyond therapeutics, contract research organizations, consumer-product companies, and environmental agencies can harness AVA to evaluate industrial chemicals, food additives, and cosmetic ingredients under human-relevant conditions—bringing faster, more ethical safety and efficacy decisions to market-driven and regulatory programs alike. Availability Global orders are open immediately. For pricing or demonstrations, please submit a request here. About Emulate Emulate, Inc. is the pioneer of Organ-on-a-Chip technology, enabling researchers to accurately replicate human tissue function and disease biology through next generation in vitro models. From target discovery to IND submission, Emulate aims to ignite a new era in human health research—one that reduces animal testing, cuts drug development costs, and accelerates the delivery of life-saving treatments. Emulate's Organ-Chip platforms, consumables, and organ models help the world's leading pharmaceutical, biotech, and academic teams generate human-relevant data that advance safer, more effective therapies. Learn more at
Business Wire
3 hours ago
- Business Wire
Workplace Injuries Are Reduced with Employee Appreciation
LOUGHTON, England--(BUSINESS WIRE)--Latest research reveals that frequently recognising employees for their efforts and achievements can decrease the likelihood of workplace injuries among French workers by up to 50%. This is a key finding from O.C. Tanner's 2025 Global Culture Report which gathered data and insights from 38,075 workers from 27 countries including 1,208 from France. The report highlights how feeling unappreciated worsens mental health and this then increases the likelihood of workplace accidents. Robert Ordever, European MD of O.C. Tanner explains: 'There's a clear link between deteriorating mental health and greater instances of workplace injuries, with mental illness often leading to decreased concentration, reduced cognitive function, and impaired decision-making abilities. Workers struggling with their mental health have their condition worsened when they feel unappreciated by their managers and colleagues.' The Report highlights how regularly recognising employees for their efforts and achievements, not only improves workers' wellbeing, but noticeably reduces the odds of them reporting a workplace accident. Employees suffering from burnout are 50% less likely to have a workplace accident when their organisation has a formal recognition programme in place. For those workers with probable depression, their odds of reporting a workplace accident are 11% when their organisation is WITHOUT a recognition programme. For workers with probable depression but WITH a recognition programme in place, their odds of reporting a workplace accident are reduced to just 8%. Ordever says, 'Implementing a recognition programme that allows all employees to regularly express gratitude to colleagues, not only reduces the likelihood of burnout, anxiety, and depression, but also cuts the number of workplace injuries. But it's important to note that having a recognition programme is not enough in itself. The organisation must champion the giving of appreciation on a daily basis, and encourage recognition that's sincere, tailored to the individual and meaningful. When the importance of recognition is understood and prioiritised, organisations can enjoy truly impactful business outcomes.' About 2025 Global Culture Report The O.C. Tanner Institute uses multiple research methods to support the Global Culture Report, including interviews, focus groups, cross-sectional surveys, and a longitudinal survey. Qualitative findings came from 27 focus groups among employees, leaders, and HR practitioners of larger organisations. About O.C. Tanner O.C. Tanner is the global leader in personalised employee recognition solutions that improve workplace cultures so people feel appreciated, do their best work, and stay. Its Culture Cloud is a suite of apps and solutions, including recognition, service awards, wellbeing, leadership, and celebrations that help people thrive at work. O.C. Tanner provides these and other services for thousands of the most respected companies in the world. For more information visit
Yahoo
5 hours ago
- Yahoo
Fit Cafe Announces Official Website Update Featuring Natural Daily Supplement for Energy, Mood, and Metabolic Support
New U.S. Wellness Brand Launches Plant-Based Morning Supplement to Support Clean Energy, Mood, and Metabolism SHERIDAN, June 09, 2025 (GLOBE NEWSWIRE) -- Fit Cafe™, a wellness-focused brand from Aspen Brass LLC, has updated its official website to share new information about its daily drink powder supplement designed to support clean energy, balanced mood, and metabolic wellness in adults. Now available in the U.S., the plant-based superfood formula offers a simple way to promote daily vitality without added sugar, gluten, or dairy. According to the official website ( Fit Cafe™ is formulated to align with the body's natural energy and digestion cycles. The company highlights the supplement's focus on convenience, offering a quick-to-mix powder that fits easily into a morning routine—no complicated diets or coffee-shop lines required. 'Fit Cafe™ is about more than just feeling energized—it's about helping people create a positive, health-forward ritual they actually enjoy,' said a company spokesperson. 'Our goal is to simplify wellness through clean, functional ingredients that support how real people live every day.' Fit Cafe™ is manufactured in quality-controlled U.S. facilities that adhere to rigorous safety standards. Its blend of superfoods, adaptogens, and nutrients is intended to support natural energy, promote a positive mood, and aid healthy metabolism—making it an ideal choice for individuals seeking a modern wellness solution without stimulants or added sugars. As noted on the official website, first-time customers are backed by a satisfaction guarantee. Full product details, ingredient information, and direct ordering options are available exclusively at About Fit Cafe™ Fit Cafe™ is a U.S.-based wellness brand developed by Aspen Brass LLC, offering natural, easy-to-use superfood supplements that support healthy daily routines. Built on a foundation of transparency and simplicity, the brand helps adults feel energized, balanced, and supported—starting with their morning ritual. Product and Contact Information Brand: Fit Cafe™Company: Aspen Brass LLCWebsite: care@ 844-240-3279Mailing Address: 1309 Coffeen Ave, Ste 17470, Sheridan, WY 82801Return Address: 4711 34th St N Suite F, St. Petersburg, FL 33714 Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. CONTACT: Email: care@ Phone: 844-240-3279 Return Address: 4711 34th St N Suite F, St. Petersburg, FL 33714
